Arguments in favor of HPV testing for cervical screening and post-treatment CIN2+ monitoring

Expert Review of Molecular Diagnostics

Volumn 14, Issue 3, 2014, Pages 245-248

  Uijterwaal, Margot H ^a   Verhoef, Viola Mj ^a   Snijders, Peter Jf ^a   Meijer, Chris Jlm ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cervical cancer; CIN; HPV; post treatment; screening; triage

Indexed keywords

TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GRADING; CANCER SCREENING; DIAGNOSTIC TEST; DISEASE MARKER; EMERGENCY HEALTH SERVICE; FEASIBILITY STUDY; HUMAN; HUMAN PAPILLOMA VIRUS TEST; REVIEW; SCREENING TEST; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY;

AFTERCARE; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; PROGNOSIS; TRIAGE; UTERINE CERVICAL NEOPLASMS;

EID: 84896937778     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.893829     Document Type: Review

References (37)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12):2893-917
2. Arbyn M, Raifu AO, Weiderpass E, et al. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009;45(15):2640-8
3. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364(9430):249-56
4. Bos AB, Rebolj M, Habbema JD, van Ballegooijen M. Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer 2006;119(10): 2372-5
5. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119(5):1095-101
6. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30(Suppl 5):F88-99
7. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13(1): 78-88
8. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357(16):1589-97
9. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009;10(7): 672-82
10. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11(3):249-57
11. Ronco G, Dillner J, Elfstrom KM, et al. The International HPV Screening Working Group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383(9916): 524-32
12. Standpunt minister van VWS screening op baarmoederhalskanker. Available from: www.rivm.nl/Documenten-en-publicaties/ Algemeen-Actueel/Uitgaven/ Preventie- Ziekte-Zorg/baarmoederhalskanker screening/Standpunt-minister-van- VWS- screening-op-baarmoederhalskanker [Last accessed 31 December 2013]
13. Gok M, Heideman DA, van Kemenade FJ, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010;340:c1040
14. Snijders PJ, Verhoef VM, Arbyn M, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 2013;132(10): 2223-36
15. Arbyn M, Verdoodt F, Snijders PJ, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014;5(2):172-83
16. J Castle PE, Sideri Meronimo J, et al. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007; 197(4):356
17. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012;130(3):602-10
18. Dijkstra M, van Niekerk D, Rijkaart D, et al. Primary hrHPV DNA testing in Cervical Cancer screening: how to manage screen positive women? A POBASCAM Trial sub study. Cancer Epidemiol Biomarkers Prev 2014;23(1):55-63
19. Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis 2013; 17(5 Suppl 1):S28-35
20. Castle PE, Stoler MH, Wright TC Jr, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011;12(9): 880-90
21. Meijer CJ, Berkhof J. Screening: cervical cancer - should we abandon cytology for screening? Nat Rev Clin Oncol 2012;9(10): 558-9
22. Petry KU, Schmidt D, Scherbring S, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol 2011;121(3):505-9
23. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009;112(2):293-9
24. Hesselink AT, Heideman DA, Steenbergen RD, et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011;17(8):2459-65
25. Eijsink JJ, Yang N, Lendvai A, et al. Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study. Gynecol Oncol 2011;120(2):280-3
26. Hesselink AT, Heideman DA, Steenbergen RD, et al. Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int J Cancer 2014. [Epub ahead of print]
27. Garcia F, Barker B, Santos C, et al. Cross-sectional study of patient- and physician-collected cervical cytology and human papillomavirus. Obstet Gynecol 2003;102(2):266-72
28. Kocken M, Uijterwaal MH, de Vries AL, et al. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol Oncol 2012;125(2):500-7
29. Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer 2006; 118(8):2048-55
30. Bleeker MC, Meijer CJ, Berkhof J. Follow-up after treatment for cervical intraepithelial neoplasia. BMJ 2012;345: e7186
31. Kocken M, Helmerhorst TJ, Berkhof J, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011;12(5):441-50
32. Denny L, Kuhn L, Hu CC, et al. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst 2010;102(20):1557-67
33. Zhao FH, Lewkowitz AK, Chen F, et al. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method. J Natl Cancer Inst 2012; 104(3):178-88
34. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360(14): 1385-94
35. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008;9(10):929-36
36. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011;378(9806): 1868-73
37. Guan Y, Castle PE, Wang S, et al. A cross-sectional study on the acceptability of self-collection for HPV testing among women in rural China. Sex Transm Infect 2012;88(7):490-4